DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)



company name or ticker

Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day

3 Reasons Johnson & Johnson Could Soar in 2015

Following a 21% year-to-date gain, Johnson & Johnson could be poised for another strong year in 2015. Find out what three catalysts could send J&J markedly higher next year.

Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog

Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Ma

Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog

Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog

Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the T

Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the Tape

Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape

Pharmacyclics, J&J Seek Imbruvica Label Expansion in EU - Analyst Blog

Up 31% in 2014, is Pharmacyclics Stock Still a Buy?

Pharmacyclics' valuation is stretched, but Imbruvica's rapid sales growth could make the case for sticking with the company.

Get Your Wallet Out: Global Drug Spending is About to Hit a Dubious Milestone

Global pharmaceutical spending is about to hit a dubious figure. Find out what this means for your pocketbook as well as your portfolio.
See More Articles...